---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003662"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-20T00:40:14.087155+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCryst extends former CFO Anthony Doyle's consulting agreement through Dec 31, 2025

## Summary
- Consulting Agreement extended from original end date to December 31, 2025; after that, month-to-month with 30-day notice.
- Mr. Doyle provides transition services related to CFO succession at $450/hour; all other terms unchanged.
- Original agreement effective April 9, 2025; extension announced on May 31, 2025.

## SEC filing metadata
- accession: 0001171843-25-003662
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325003662/0001171843-25-003662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325003662/f8k_060325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003662
- JSON: https://secwatch.observer/filing/0001171843-25-003662.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.